A UK-based SME specialising in toxicology offers its team with over 150 years' expertise in integrated toxicology and scientific strategy to companies, universities and research institutions in the pharmaceutical sector. The SME will help partners develop and deliver innovative discovery and development strategies. It is envisaged that this partnership will take the form of a services agreement although research cooperations through joint venture agreements will also be considered.
During the course of research into new active molecules in the pharmaceutical sector, large libraries of related compounds may be generated. These molecules will have different activity and toxicity profiles and developing a strategy for finding and developing the optimal ones that are fit for purpose can be time consuming and challenging. This is especially the case for smaller companies, universities and research institutions who may lack the specific expertise and knowledge required for this type of development process, impeding the introduction of new therapeutics to the market. A UK-based consultancy and laboratory-based SME is offering flexible access to a team with over 150 years of expertise in the field. The SME has toxicology expertise from early evaluation of target and chemistry through to development, registration and life cycle management. They can help partners design, develop, communicate and publish their scientific strategies and data in order to effectively select optimal compounds and take them through the whole development process. In addition the SME can also provide mechanistic problem solving to understand mode of action of toxicities in nonclinical species and understand relevance to humans. This will de-risk further development by screening out molecules with unacceptable high toxicity and enabling further drug design incorporating the chemistry features associated with reduced toxicity. The SME is looking to partner with early-stage pharmaceutical companies as well as universities and research institutions working in the pharmaceutical and drug discovery sectors. The SME will provide their expertise to enable partners to identify candidates from compound libraries they have generated during the course of research projects for further development. It is envisaged that this partnership will take the form of a services agreement, although if it is appropriate to incorporate this scientific strategy support as part of an overarching research project then research cooperations through joint venture agreements will also be considered.
Innovations and advantages
The SME's scientific and data strategy support offer has the following advantages: Over 150 years of combined experience in the field of drug discovery and toxicology enabling the best strategy to be selected or developed to provide robust data that suits the individual requirements of the client's project. Multiple areas of expertise (early evaluation of target and chemistry, regulatory, genetic toxicology, problem-solving, study monitoring, devices, contract research organisation audit, good laboratory practice). This will allow the SME to best advise the client on any toxicity issues shown by their compound library and how to overcome them. Experience with multiple platforms (small molecules, biologics, new modalities, regenerative medicine) enabling expert advice on these different molecules categories to be given. Worldwide regulatory experience enabling strategic advice to be given with regulatory requirements in mind to streamline further development by enabling candidate molecules that would not pass regulatory requirements to be screened out at an early stage of development saving costs and time. Diverse industrial project, people and laboratory management experience enables the SME to provide support even on projects involving challenging new compounds.
06002001 Biochemistry / Biophysics
06002002 Cellular and Molecular Biology
Market application codes
05003001 Therapeutic services
05007002 Pharmaceuticals/fine chemicals
Intellectual property rights
Type of partner sought
The SME is looking to partner with early-stage pharmaceutical companies as well as universities and research institutions working on new therapeutic molecules. The SME offers its expertise in integrated toxicology and scientific strategy to enable partners to identify compounds of interest from libraries they have generated during the course of their research for further research and development. They will also help partners design, develop, communicate and publish their scientific strategies and data in order to effectively select optimal compounds and take them through the whole development process including regulation. It is envisaged that the partnership will take the form of a services agreement. However if the scientific strategy support forms part of a research project then research cooperations through joint venture agreements will also be considered if this would be more appropriate.